Vira-A en es it fr

Vira-A Brand names, Vira-A Analogs

Vira-A Brand Names Mixture

  • No information avaliable

Vira-A Chemical_Formula


Vira-A RX_link

Vira-A fda sheet

Vira-A msds (material safety sheet)

Vira-A Synthesis Reference

No information avaliable

Vira-A Molecular Weight

285.257 g/mol

Vira-A Melting Point

No information avaliable

Vira-A H2O Solubility

No information avaliable

Vira-A State


Vira-A LogP


Vira-A Dosage Forms

No information avaliable

Vira-A Indication

For treatment of chickenpox - varicella, herpes zoster and herpes simplex

Vira-A Pharmacology

Vidarabine is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. in vitro, Vidarabine triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, Vidarabine triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where Vidarabine triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand.

Vira-A Absorption

No information avaliable

Vira-A side effects and Toxicity

No information avaliable

Vira-A Patient Information

No information avaliable

Vira-A Organisms Affected

Human Herpes Viruses